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Summary
 
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an important regulator of T cell homeostasis.
Ligation of this receptor leads to prominent downregulation of T cell proliferation, mainly as a
consequence of interference with IL-2 production. We here report that CTLA-4 engagement
strikingly selectively shuts off activation of downstream T cell receptor (TCR)/CD28 signaling
events, i.e., activation of the microtubule-associated protein kinase (MAPKs) ERK and JNK.
In sharp contrast, proximal TCR signaling events such as ZAP70 and TCR-
 
z
 
 chain phosphor-
ylation are not affected by CTLA-4 engagement on activated T cells. Since activation of the
ERK and JNK kinases is required for stimulation of interleukin (IL)-2 transcription, these data
provide a molecular explanation for the block in IL-2 production imposed by CTLA-4.
 
A
 
ctivated T cells are subject to a number of downregu-
latory mechanisms designed to maintain T cell homeo-
stasis, and several receptors involved in this process have been
identified. Among these are the CD95 and the TNF recep-
tor which both trigger apoptotic pathways (1, 2). Recently,
it has become clear that CTLA-4 also downregulates T cell
responses (for reviews see references 3, 4). Antibodies to
CTLA-4 can, when crosslinked, prevent proliferation and
IL-2 production of T cells stimulated through the TCR,
whereas (blocking) Fab fragments of anti–CTLA-4 can ac-
tually enhance T cell responses (5–8). The physiological
relevance of these findings is dramatically demonstrated by
the phenotype of mutant mice lacking CTLA-4; such mice
develop severe lymphoproliferative disease and massive lym-
phocytic infiltration and tissue destruction that is lethal by
3–4 wk of age (9, 10). The potential of CTLA-4 as a nega-
tive regulatory receptor is also illustrated by the recent find-
ings that in vivo blockage of CTLA-4 retards the growth of
an immunogenic tumor, implying augmented T cell–medi-
ated antitumor immunity (11). Moreover, similar in vivo
blockage of CTLA-4 has been found to markedly exacer-
bate disease in mice induced to develop experimental aller-
gic encephalytis (EAE)
 
1
 
 (12).
CTLA-4 function is regulated by engagement with its
ligands CD80 and CD86 on antigen-presenting cells (13).
These molecules also regulate the function of CD28, a re-
ceptor promoting T cell activation and persistence of T cell
responses by enhancing IL-2 production and expression of
survival factors (for review see reference 4). How the same
ligands can induce such opposite processes in T cells depend-
ing on the receptor engaged may be explained by the dif-
ferent expression patterns of CD28 and CTLA-4. Although
CD28 is expressed constitutively on all T cells, CTLA-4 is
expressed only after activation, reaching its peak after 48 h
(6, 14–16). These expression patterns suggest that during
the initial phase of T cell activation, CD28 may dominate
the response to CD80/CD86. At later times after activation,
CD80/CD86 molecules might downregulate the response
by engaging CTLA-4. However, CTLA-4 can already func-
tion during the first 24 h of activation as demonstrated by
antibody cross-linking studies, suggesting that CTLA-4 may
also play a role in setting a threshold for activation (7).
Two nonmutually exclusive models have been proposed
for the mode of action of CTLA-4 (17). First, CTLA-4 may
specifically antagonize CD28 function, either by compet-
ing for CD80/CD86 molecules and/or by actively block-
ing CD28 signal transduction. The finding that the inhibi-
tory effects of cross-linked anti–CTLA-4 can be overcome,
to some extent, by addition of high doses of anti-CD28
might be interpreted as support for this model (6). Alterna-
tively, CTLA-4 might interfere with TCR signaling as sug-
gested by the hyperactivity of kinases associated with the
TCR such as Lck and Fyn, as well as hyperphosphorylation
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of TCR-
 
z
 
 and ZAP70 in T cells from CTLA-4 knockout
mice (18).
The present study was designed to gain insight into the
mechanism(s) used by CTLA-4 for negative regulation of
T cell responses by directly examining signal transduction
associated with CTLA-4 triggering. Using preactivated T
cells, we find that CTLA-4 coengagement with the antigen
receptor and CD28 leads to a reduction in the activities of
both jun NH
 
2
 
-terminal kinase (JNK) and extracellular signal-
regulated-kinase 2 (ERK-2). Since ERK2 activity induced
by TCR engagement alone (i.e., in the absence of CD28
triggering) was also blocked by CTLA-4 engagement, these
data demonstrate that CTLA-4 interferes with TCR signal
transduction independently of any possible effects on
CD28-mediated events. However, anti-CD3–induced
phosphorylation of TCR-
 
z
 
 and of ZAP70 were found to
be unaffected by CTLA-4 engagement. Thus, our data
demonstrate that CTLA-4 imposes a block in TCR-medi-
ated signal transduction downstream of these early events,
but upstream of ERK2 and JNK. As these kinases play cru-
cial roles in induction of IL-2 transcription (19–21), this
finding provides a molecular explanation for the block in
IL-2 production that results from CTLA-4 engagement.
 
Materials and Methods
 
Mice.
 
Lymph nodes were isolated from C57BL/6 mice (6–8-
wk-old). The mice were bred at The Netherlands Cancer Insti-
tute (Amsterdam, The Netherlands) under specific pathogen-free
conditions.
 
Media, Antibodies, and Other Reagents.
 
Iscove’s modified Dul-
becco’s medium (GIBCO BRL, Paisley, UK) was supplemented
with 10% FCS (BioWhittaker, Inc., Verviers, Belgium), 100 U/ml
penicillin, 100 mg/ml streptomycin, and 2 
 
3
 
 10
 
2
 
5
 
 M 2-mercap-
toethanol (Merck, Darmstadt, Germany).
The following antibodies were used in this study: 145.2C11
(anti-CD3; reference 22) and M5/114 (anti-MHC II; American
Type Culture Collection, Rockville, MD); 37.51 (anti-CD28; ref-
erence 23), UC10-4F10-11 (anti–CTLA-4; PharMingen, San Di-
ego, CA); goat anti–hamster IgG (H 
 
1
 
 L; Pierce, Rockford, IL);
4G10 (antiphosphotyrosine; Upstate Biotechnology Inc., Lake Pla-
cid, NY); rabbit anti–mouse and swine anti–rabbit peroxidase-con-
jugated antibodies (DAKO, Glostrup, Denmark); rabbit polyclonal
IgG anti–ERK2 and rabbit polyclonal IgG anti-JNK1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA); 6B10.2.5 (anti–TCR-
 
z
 
–PO4) and 1E7.2 (anti–ZAP70) were provided by Drs. H. van
Oers and A. Weiss.
Production and purification of glutathione-
 
S
 
-transferase (GST)–
c-Jun (1–135) was performed as described (24). MBP was pur-
chased from Sigma Chemical Co. (St. Louis, MO).
 
T Cell Stimulation.
 
T cells were purified from lymph node
cell suspensions as follows. Nylon wool passed (NWP) lymph
node cells were incubated with anti–class II mAb (M5/114). The
NWP lymph node cells were depleted of antibody binding cells
through magnetic bead depletion using goat anti–mouse Ig beads
(Advanced Magnetics, Cambridge, MA) and sheep anti–rat Ig
beads (Dynal, Oslo, Norway). T cell preparations were typically
 
.
 
98% pure by anti-CD3 staining.
To induce CTLA-4 expression, purified T cells (4 
 
3
 
 10
 
6
 
 cells/
well) were preactivated in 24-well plates coated with anti-CD3
and anti-CD28 mAbs (10 
 
m
 
g/ml each). After 40 h, cells were
harvested and then rested for 5 h in 10% FCS–containing me-
dium at 37
 
8
 
C. Purified naive (fresh cells rested in vitro for 5 h in
10% FCS–containing medium at 37
 
8
 
C) or preactivated T cells
were incubated in medium with anti-CD3, anti-CD28, and anti–
CTLA-4 (each at 10 
 
m
 
g/ml) at the indicated combinations for 30
min on ice. Cells were washed twice with cold medium and goat
anti–hamster antibody was added at 10 
 
m
 
g/ml in warm (37
 
8
 
C)
medium. After this, cells were incubated for the indicated times at
37
 
8
 
C. The reactions were stopped by addition of ice-cold PBS af-
ter which the cells were spun down. Subsequently, cells were lysed
as described below.
 
ERK2 and JNK Kinase Assays.
 
Cells were lysed for 30 min
on ice with whole cell extract lysis buffer (25 mM Hepes at pH
7.7, 0.3 M NaCl, 1.5 mM MgCl
 
2
 
, 0.2 mM EDTA, 0.1% Triton
X-100, 0.5 mM dithiothreitol [DTT], 20 mM 
 
b
 
-glycerolphosphate,
0.1 mM Na
 
3
 
VO
 
4
 
, 2 
 
m
 
g/ml of leupeptin, and 1 mM of PMSF) (25).
Lysates were cleared by centrifugation at 14,000 
 
g
 
 for 10 min at
4
 
8
 
C. Protein concentration was determined using the bicinchininic
acid protein assay (Pierce), and 40 
 
m
 
g of total protein/lane was
used for immunoprecipitation. Whole cell extracts were diluted
to get as final concentration of the buffer: 20 mM Hepes at pH
7.7, 75 mM NaCl, 2.5 mM MgCl
 
2
 
, 0.1 mM EDTA, 0.05% Triton
X-100, 0.5 mM DTT, 20 mM 
 
b
 
-glycerol phosphate, 0.1 mM
Na
 
3
 
VO
 
4
 
, 2 
 
m
 
g/ml of leupeptin, and 1 mM of PMSF. For JNK
precipitation, cell extracts were incubated overnight (o/n) at 4
 
8
 
C
with 10 
 
m
 
g of GST–c-Jun bound to glutathione-agarose beads
(Sigma Chemical Co.). Precipitates were washed 4 times with
Hepes binding buffer (20 mM Hepes at pH 7.7, 50 mM NaCl,
2.5 mM MgCl
 
2
 
, 0.1 mM EDTA, and 0.05% Triton X-100), and
subsequently resuspended in 30 
 
m
 
l of kinase buffer (20 mM
Hepes at pH 7.6, 20 mM MgCl
 
2
 
, 20 mM 
 
b
 
-glycerolphosphate,
20 mM paranitro phenyl phosphate, 0.1 mM Na
 
3
 
VO
 
4
 
, and 2 mM
DTT) containing 20 
 
m
 
M cold ATP and 5 
 
m
 
Ci of 
 
g
 
-[
 
32
 
P]ATP.
After 20 min at 37
 
8
 
C the reaction was stopped by washing the
beads 3 times with Hepes binding buffer. GST–c-Jun was eluted
and resolved on 10% SDS-PAGE gel.
For ERK2 immunoprecipitation, the cell extracts were incubated
o/n at 4
 
8
 
C with 1 
 
m
 
g anti-ERK2 bound to protein A–Sepharose
beads (Pharmacia Biotech, Uppsala, Sweden). Immunoprecipi-
tates were washed 3 times with 50 mM Tris, pH 7.5, 100 mM
NaCl, 1 mM EGTA, 20 mM 
 
b
 
-glycerolphosphate, 0.1 mM
Na
 
3
 
VO
 
4
 
, and once with 20 mM Hepes of pH 7.5, 0.5 mM MnCl
 
2
 
,
10 mM MgCl
 
2
 
, 1 mM EGTA, 20 mM 
 
b
 
-glycerolphosphate, and
0.1 mM Na
 
3
 
VO
 
4
 
. Kinase reactions were performed at 37
 
8
 
C in 30
 
m
 
l of kinase buffer containing 20 mM Hepes of pH 7.5, 0.5 mM
MnCl
 
2
 
, 10 mM MgCl
 
2
 
, 1 mM EGTA, 1 mM DTT, 0.3 mg/ml
MBP, 25 
 
m
 
M cold ATP, and 5 
 
m
 
Ci of 
 
g
 
-[
 
32
 
P]ATP. After 20 min,
the reaction was finished by adding 5 
 
m
 
l of 5
 
3
 
 sample buffer.
Samples were boiled and resolved on 12.5% SDS-PAGE. Phos-
phorylation of GST–c-Jun and MBP was visualized and the radio-
activity of each band quantified using a phosphorimager.
For ERK2 and JNK immunoblots, proteins from total lysates
were resolved on 10% SDS-PAGE and transferred onto nitrocel-
lulose membranes (Schleicher & Schuell, Dassel, Germany). Mem-
branes were blocked o/n at 4
 
8
 
C with 10 mM Tris-HCl of pH
8.0, 150 mM NaCl, 0.2% Tween 20, and 10% nonfat milk (Pro-
fitar, Nutricia, Holland). After blocking, membranes were blotted
with polyclonal rabbit anti-ERK2 or anti-JNK antibodies, respec-
tively, followed by a swine anti–rabbit peroxidase-conjugated an-
tibody. Blots were developed using enhanced chemiluminescence
(Amersham Intl., Buckinghamshire, UK).
 
TCR-
 
z
 
 Chain and ZAP70 Immunoprecipitation and Immunoblot-
ting.
 
Preactivated T cells were lysed in lysis buffer containing 20 
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mM Tris-HCl of pH 7.6, 150 mM NaCl, 2 mM EDTA, and
protease and phosphatase inhibitors. After 30 min of incubation
on ice, lysates were cleared by centrifugation and incubated o/n
at 4
 
8
 
C with anti-TCR-
 
z
 
 chain or anti-ZAP70 antibodies bound
to Sepharose–protein A beads. Beads were washed 3 times with
lysis buffer and proteins eluted by boiling in 2
 
3
 
 sample buffer.
Proteins were resolved in SDS-PAGE gels, transferred to polyvi-
nylidene difluoride membranes (Millipore, Bedford, Massachu-
setts), and blocked o/n in PBS, 0.2% Tween 20, and 1% BSA.
Tyrosine phosphorylation was detected with antiphosphotyrosine
antibody followed by rabbit anti–mouse peroxidase-conjugated
secondary antibody. Blots were developed using enhanced
chemiluminescence.
 
Results
 
ERK2 Activity Is Reduced upon CTLA-4 Engagement.
 
Studying the individual contributions to T cell activation of
the CD28 and CTLA-4 receptors is complicated by the fact
that both receptors are triggered by the same ligands, the
CD80/CD86 molecules. However, the availability of mAbs
to CD28 and CTLA-4 has made it possible to separately
investigate the functions of these receptors. The inhibitory
role of CTLA-4 in T cell activation has now been visual-
ized in several studies (5–8). The block imposed by CTLA-4
engagement on T cell activation predominantly results from
interference with IL-2 production (6, 8), resulting in inhi-
bition of cell cycle progression.
The ERK family of MAP kinases has been found to be
required for stimulation of IL-2 transcription (19, 26). There-
fore, we investigated whether the activity of ERK2 would
be affected by CTLA-4 triggering. Because CTLA-4 has been
reported to be expressed only after activation, peaking after
2 d (6), we first preactivated T cells purified from lymph
nodes for 40 h on plates coated with anti-CD3 and anti-
CD28. After harvesting, we incubated the preactivated cells
in fresh medium for an additional 5 h, as we observed that
immediately after the 40-h activation period, ERK2 and
JNK were too strongly activated to allow visualization of
induction by TCR triggering (data not shown). After this
5-h incubation, cells were stimulated with different combi-
nations of antibodies as indicated, and lysed. In vitro kinase
reactions were performed with anti-ERK2 immunoprecip-
itates from these lysates. As has been shown previously (20,
27), efficient ERK2 activation can be achieved by trigger-
ing the TCR alone (Fig. 1 
 
A
 
). However, in lysates derived
from cells on which CTLA-4 is coengaged together with
the antigen receptor, ERK2 activity is almost abrogated.
Shown here are the results obtained with cells lysed 1 min
after cross-linking the antibodies. In most experiments at
this time point, anti-CD3–induced ERK2 activity has
reached its maximum, being undetectable by 5 min after
stimulation. However, in experiments in which anti-CD3–
induced ERK2 activity persisted longer, this activity was
still reduced by CTLA-4 engagement at 5 min after triggering
(data not shown). The pronounced anti–CTLA-4–induced
reduction in ERK2 activity in preactivated cells is con-
trasted with results in freshly isolated T cells in which no
effect of addition of anti–CTLA-4 on ERK2 activity was ob-
served (Fig. 1 
 
B
 
). These findings are consistent with the re-
ported requirement for activation of CTLA-4 expression.
In contrast to earlier published results that suggest that
ERK2 activity is not affected by CD28 triggering (20, 27),
we consistently found that in cells stimulated with anti-
CD3 and anti-CD28, ERK2 activity is somewhat higher
(Fig. 1). Moreover, we found that ERK2 activity induced
in the presence of anti-CD28 usually persisted longer than
ERK2 activity induced by TCR triggering alone, reaching
its peak by 10 min after activation (Fig. 2). Interestingly, an
effect of CD28 signaling on ERK2 activity is also revealed
by the finding that 1 min after stimulation the inhibition of
ERK2 activity/activation by CTLA-4 is prevented by anti-
CD28 (compare Figs. 1 
 
A
 
 and 2). At later time points,
however, anti-CD3– and anti-CD28–induced ERK2 ac-
tivity is also downregulated by CTLA-4 (Fig. 2) with al-
most complete inhibition at 10 min. Together, these results
demonstrate that CTLA-4 on preactivated T cells down-
regulates TCR-induced ERK2 activity, either by interfer-
ing with activation of this kinase or by directly modulating
ERK2 kinase activity.
 
JNK Activity Is Reduced upon CTLA-4 Engagement.
 
Like the ERKs, the JNK family of MAP kinases have been
implicated in induction of IL-2 gene transcription, as these
enzymes phosphorylate the NH
 
2
 
 terminus of c-Jun and
thereby enhance its transcriptional activity (20, 21, 25, 28,
29). We therefore tested whether the activity of JNK might
also be regulated by CTLA-4. JNKs bind with high affinity
to c-Jun, such that these kinases can be precipitated from cell
lysates with immobilized GST–c-Jun coupled to beads
(25), after which in vitro kinase reactions can be per-
formed. It has been shown in both Jurkat T cells and in T
Figure 1. CTLA-4 inhibits
ERK2 activity induced by anti-
CD3 in preactivated T cells, but
not in naive T cells. (A) 2-d pre-
activated T cells were coated on
ice with the indicated combina-
tions of anti-CD3, anti-CD28,
and anti–CTLA-4. 1 min after
addition of cross-linking anti–
hamster antibody (10 mg/ml) in
warm (378C) medium the cells
were lysed, ERK2 was immuno-
precipitated, and in vitro kinase
reactions were performed using
MBP as substrate in the presence
of g-[32P]ATP. Indicated by ar-
rows are the bands representing
phosphorylated MBP (top). The
same lysates were tested for equal
protein abundance on immuno-
blot (bottom). (B) Naive purified
T cells were rested for 5 h and
coated with the different combi-
nations of antibodies as indi-
cated. Cells were lysed 1 or 5
min after addition of warm
cross-linking antibody and in
vitro kinase reactions were per-
formed as in A. 
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cell clones that activation of JNKs by TCR triggering is
dependent on costimulation (20, 27). Indeed, we find that
also in these preactivated primary T cells, JNK activity is
only induced if CD3 triggering is accompanied by CD28
engagement (Fig. 3). Cocross-linking with anti–CTLA-4
results in a clear reduction in JNK activity, demonstrating
that CTLA-4 also interferes with the activation or activity
of these kinases involved in induction of IL-2 transcription.
Whether this reflects a direct effect of CTLA-4 on JNK
pathway components or is a consequence of CTLA-4–
induced abrogation of TCR signaling remains to be inves-
tigated.
 
CTLA-4 Does Not Affect Early Parameters of TCR Trigger-
ing.
 
The data presented above demonstrate that CTLA-4
imposes a block in signal transduction upstream or at the
level of ERK2 and JNK. Furthermore, these findings doc-
ument that CTLA-4 has an effect on signal transduction
events induced by TCR triggering independent of CD28
engagement, as ERK2 activity induced by anti-CD3 alone
was reduced upon coengagement of CTLA-4 (Fig. 1 
 
A
 
). A
role for CTLA-4 counteracting early activation events asso-
ciated with TCR signal transduction is also suggested by
findings in T cells derived from CTLA-4–deficient mice.
Thus, in CTLA-4
 
2
 
/
 
2
 
 cells, proteins such as TCR-
 
z
 
 and
ZAP70 are constitutively hyperphosphorylated (18). For
these reasons, we directly investigated whether anti-CD3–
induced TCR-
 
z
 
 phosphorylation and ZAP70 phosphoryla-
tion are affected by CTLA-4 triggering.
The TCR-
 
z
 
 chain contains three so-called ITAMs (im-
munoreceptor tyrosine based activation motif) sequences
that are necessary for coupling the TCR to the intracellular
signaling machinery (30–32). Upon TCR activation, these
motifs become phosphorylated on tyrosine residues as a con-
sequence of which the electrophoretic mobility of the pro-
tein changes (33, 34). We immunoprecipitated TCR-
 
z
 
 from
lysates obtained as described above using an antibody spe-
cific for phosphorylated TCR-
 
z
 
. After immunoblotting the
precipitates with an antibody against phosphotyrosine, bands
of 21 kD and p23 kD were visualized, representing differ-
ent phosphorylated isoforms of TCR-
 
z
 
 (Fig. 4 
 
A
 
; reference
34). Although the 21-kD band was also present in unstim-
ulated cells as previously reported for fresh lymph node T
cells (35, 36), the p23 band specifically appeared after CD3
triggering. Importantly, at none of the time points exam-
ined was the intensity of either one of these two phospho-
 
z
 
bands altered upon coengagement of CTLA-4 with CD3
(Fig. 4 
 
A). Yet, in these same cells, ERK2 activity was again
abrogated by CTLA-4 engagement (data not shown). We
conclude that z-phosphorylation is not affected by CTLA-4.
Phosphorylation of TCR-z allows binding of ZAP70 via
its SH2 domains (37). Moreover, the recruited ZAP70 mole-
cules become phosphorylated on tyrosine residues shortly
after TCR triggering, leading to activation of this kinase
(36, 38, 39). To investigate potential effects of CTLA-4 on
ZAP70 phosphorylation, we immunoprecipitated this ki-
nase and immunoblotted with an antiphosphotyrosine anti-
body. As shown in Fig. 4 B, phosphorylation of ZAP70 at
1 min after stimulation was not affected by CTLA-4 en-
gagement. Similarly, we found no changes in the phosphor-
ylation state of this kinase at later time points (data not
shown). Together, these data strongly suggest that the block
imposed by CTLA-4 resulting in decreased ERK and JNK
activity lies downstream of the TCR proximal events that
result in phosphorylation of TCR-z and ZAP70.
Discussion
CTLA-4 is an important regulator of peripheral T cell
homeostasis by virtue of its ability to negatively regulate T
cell expansion. Although the functional consequences of
CTLA-4 engagement have been studied extensively in
Figure 2. Combined trigger-
ing of CD3 and CD28 delays
downregulation of ERK2 activ-
ity by CTLA-4. Preactivated T
cells were coated with different
combinations of antibodies as in
Fig. 1 and lysed 1, 5, or 10 min
after addition of warm cross-
linking antibody. ERK2 was im-
munoprecipitated and in vitro
kinase reactions were performed
(top). The same lysates were
tested for ERK2 protein abun-
dance (middle). ERK2 activities
were quantified using a phos-
phorimager and represented as
relative values compared to
ERK2 activities from unstimu-
lated cells (unstimulated 5 1;
bottom).
Figure 3. CTLA-4 reduces
JNK activity induced by CD3
and CD28 triggering. Preacti-
vated T cells were coated with
different combinations of anti-
bodies and lysed 10 min after ad-
dition of warm cross-linking an-
tibody. Lysates were tested for
JNK activity by precipitation
with GST–c-jun precoupled to
glutathione beads followed by in
vitro kinase reactions as de-
scribed in Materials and Meth-
ods. Phosphorylated GST–c-jun is
indicated by the arrow (top). The
same lysates were tested for JNK
protein abundance on immuno-
blot (middle). JNK activities were
quantified using a phosphorim-
ager and represented as relative
values compared to JNK activity
from unstimulated cells (unstim-
ulated 5 1; bottom). Data for the
10-min time point are shown
because no JNK activity could
be measured at earlier times.1649 Calvo et al.
vitro and in vivo (3), very little is known about the signal-
ing events resulting from ligation of this receptor. Some in-
vestigators have reported a receptor-ligation–inducible as-
sociation of PI3 kinase with the cytoplasmic tail of CTLA-4
(40). However, as the same kinase also binds to the cyto-
plasmic tail of CD28 (41), it seems unlikely that association
of this kinase with CTLA-4 would explain its inhibitory ef-
fects on induction of T cell proliferation. It has also been
suggested that the role of PI3 kinase binding to CTLA-4
may be to regulate transport of this receptor, most of which
is localized in intracellular vesicles, to the cell surface (42–
44). Other investigators have found that a phosphatase termed
Syp (also known as SHP2 or PTP1D) can be coimmuno-
precipitated with CTLA-4 (18). Furthermore, it was shown
that these precipitates could dephosphorylate the adapter
protein Shc (see below) in vitro. In apparent agreement
with a role for a phosphatase in the function of CTLA-4,
these same investigators showed that in T cells derived from
CTLA-4–deficient mice, the kinases Fyn, Lck, and ZAP70
were hyperactivated (18). Also, other proteins such as
TCR-z and Shc, were constitutively hyperphosphorylated
in CTLA-42/2 mice (18). However, rather than being a
direct consequence of the absence of CTLA-4, such obser-
vations might also result from the hyperactivated state of T
cells in CTLA-4–deficient mice (9, 10).
In the present study, we used preactivated T cells to di-
rectly investigate how CTLA-4 engagement influences sig-
nal transduction events associated with T cell activation.
We found that antigen receptor and CD28-mediated acti-
vation of the MAP kinases ERK2 and JNK is impeded upon
coengagement of CTLA-4. In sharp contrast, phosphoryla-
tion of TCR-z and ZAP70 were unaffected by CTLA-4
triggering. CTLA-4–induced T cell inactivation is thus linked
to defective ERK and JNK activation, and occurs down-
stream of immediate TCR signaling events.
It has been suggested that one way in which CTLA-4
may function might be by counteracting the consequences
of CD28 signaling (17). This proposal resulted from the
observation that high doses of an antibody to CD28 can, at
least to some extent, rescue T cell proliferation from anti–
CTLA-4–induced inhibition (6). The present data, how-
ever, unequivocally demonstrate that CTLA-4 interferes
with signal transduction events induced by the TCR inde-
pendent of CD28 triggering. These findings are therefore
consistent with the hypothesis that CTLA-4 interferes di-
rectly with downstream TCR signaling events. In addition,
CTLA-4 may affect signal transduction through CD28, as
suggested by the reduction in JNK activity induced by anti–
CTLA-4. Whether this reflects a direct or indirect effect re-
mains to be investigated. The “rescuing” effects of anti-
CD28 on T cell proliferation may in fact be the result of
modulation of TCR signaling by CD28. In support of this
possibility, we found anti-CD28 to affect both the strength
and the persistence of ERK2 activity induced by TCR sig-
naling. Indeed, it also prevented the blockade of TCR-
induced ERK2 activity by CTLA-4 at early time points after
activation. Although at later time points the CTLA-4–induced
block in ERK2 activity did manifest itself despite CD28
engagement, it is conceivable that at lower concentrations
of anti–CTLA-4 or higher concentrations of anti-CD28,
rescuing effects from CD28 became dominant. A domi-
nance of CD28 over CTLA-4 might be relevant in situa-
tions in which CTLA-4 expression on T cells is still low
and CD80/CD86 expression is relatively high.
In view of a recent suggestion (45) that CTLA-4 can ac-
tually also provide positive costimulatory signals in T cell acti-
vation, it will be interesting to compare the signaling path-
ways emanating from TCR and CTLA-4 under conditions
that visualize either positive or negative effects of CTLA-4
engagement. Our experiments were performed under con-
ditions in which CTLA-4 engagement results in an abroga-
tion of IL-2 production, and such findings have been docu-
mented by many laboratories (for review see references 3,
17). A role for CTLA-4 in blocking IL-2 production is also
consistent with the phenotype of CTLA-42/2 mice (9, 10).
Nevertheless, a positive regulatory effect of CTLA-4 may,
Figure 4. Anti-CD3–induced phosphorylation of TCR-z and ZAP70 is not affected by CTLA-4. (A) Preactivated T cells were coated with different
combinations of antibodies and lysed 1, 5, or 10 min after addition of warm cross-linking antibody. TCR-z was immunoprecipitated and immunoblotted
with antiphosphotyrosine antibody 4G10. Indicated with arrows are the p21 and p23 isoforms of tyrosine phosphorylated TCR-z. (B) Lysates prepared as
in A from cells stimulated for 1 min were immunoprecipitated with anti-ZAP70 antibody and immunoblotted with antiphosphotyrosine antibody 4G10.
Indicated with an arrow is phosphorylated ZAP70. Similar results were also obtained on lysates from 5 and 10 min–stimulated cells (not shown).1650 Effects of CTLA-4 Engagement on T Cell Signaling
under other conditions (45), dominate the response, al-
though the latter studies (45) did not exclude an adhesive
interaction between CTLA-4 and CD80, allowing other
costimulatory receptors to exert their effect.
Another issue that remains to be resolved is to which ex-
tent the antibody-mediated cross-linking of TCR/CD28/
CTLA-4 used in this study truly reflect physiological,
ligand-triggered events. An example of the different out-
come between antibody- and ligand-mediated triggering
was revealed some years ago by the Cantrell laboratory
(ICRF, London, UK); although antibody-mediated trig-
gering of CD28 resulted in p21ras activation, CD80-medi-
ated triggering did not (46). An alternative explanation for
those observations, however, might be that the CD80 ligand
triggered both CD28 and CTLA-4, and actively abrogated
p21ras activation. Antibodies to CD28, on the other hand,
would allow activation of p21ras to be revealed. Until recip-
rocal mutants of CD80 or CD86 become available that
selectively bind to either CD28 or CTLA-4, the issue of
whether the anti–CTLA-4 triggered inhibitory effects on
downstream TCR signaling events mimic ligand-induced
events remains to be tested. It should be kept in mind, how-
ever, that the observed modulatory effect of anti–CTLA-4
on the MAPKs are consistent with the results of earlier
functional studies (5–12) both in vitro and in vivo.
The inhibition of T cell proliferation by CTLA-4 en-
gagement can be overcome by addition of IL-2 (8; data not
shown). This suggests that the blockade of proliferation by
CTLA-4 is predominantly a consequence of its interference
with IL-2 production. The data presented here provide a
molecular explanation for this interference, since both the
ERKs and the JNKs are involved in induction of IL-2 gene
transcription. A well documented role for the ERKs is
phosphorylation of ternary complex factor (TCF)/Elk-1
(47–49), stimulating it to activate c-fos transcription. JNKs,
on the other hand, enhance the transcriptional activity of
c-Jun by NH2-terminal phosphorylation (25). Together, Fos
and Jun proteins form AP1 complexes that bind to a func-
tionally important AP1 site in the IL-2 promotor and, in
addition, participate in formation of NFAT and NF–IL-2
(50–53). Transfection studies have established that, at least
in transformed T cell lines, ERK activity is indeed required
for IL-2 promotor–driven gene transcription (19). Further-
more, JNK activity also appears to be required, since trans-
fected Jun mutants that cannot be phosphorylated inhibit
IL-2 promotor activity in luciferase reporter assays (20).
Although in theory inhibition of either pathway alone
might be sufficient to severely restrict IL-2 production, in-
hibition of both pathways probably results in a more pro-
nounced block. The simplest explanation for how both of
these kinases are inhibited would be that CTLA-4 inhibits
a target that is commonly involved in turning on both cas-
cades. As TCR triggering is required for activation of ERKs
as well as of JNKs (20, 27, and this paper), this target would
have to be activated by TCR triggering alone and lie down-
stream of TCR-z phosphorylation. In this respect, it would
be attractive to speculate that CTLA-4 inhibits TCR signal
transduction at the level of or upstream of p21ras. It is well
established that in many cell types, including T cells, p21ras
activates and is required for activation of ERK1 and ERK2
(54–56). Moreover, although Ras activity alone is insuffi-
cient to activate JNK in T cells, it has been reported that
overexpression of a gene encoding dominant negative Ras
does inhibit JNK activation (21). Consistent with an effect
on Ras, others have observed that anti-Syp as well as anti–
CTLA-4 immunoprecipitates could, in vitro, dephosphor-
ylate the adaptor protein Shc (18), a protein that is used by
various receptor tyrosine kinases for activation of p21ras via
its association with Grb2–Sos complexes (57–60). Although
the in vivo relevance of this in vitro dephosphorylation ac-
tivity still remains to be established, these data might pro-
vide an explanation for the results presented here by us.
However, there is some controversy about whether Shc is
in fact involved in TCR-mediated Ras activation. Thus,
although T cell hybridomas complexes of Shc-Grb2-SOS
complexes were found after TCR cross-linking (61), such
complexes could not be detected in TCR-activated periph-
eral blood T cells (62). Instead, in these latter cells, Grb-2 and
Sos, were found complexed with another adapter of
z36–38 kD, possibly the recently cloned p36lnk (63, 64).
Furthermore, additional mechanisms, not involving Grb2–
Sos, exist for TCR-mediated Ras activation in T cells, in-
cluding inhibition of Ras GTPase–activating proteins (Ras-
GAP) as well as PKC-mediated regulation (65, 66). Finally,
in signaling from several receptor tyrosine kinases, the
phosphatase Syp has actually been reported to stimulate
rather than inhibit growth factor–induced ras and MAPK
activation (67, 68). Thus, it is unclear whether possible ef-
fects from CTLA-4–associated Syp would provide a satisfac-
tory explanation for the inhibition of ERK and JNK activa-
tion we here report. Nevertheless, involvement of a
phosphatase seems conceptually appealing, given the role of
phosphatases in inhibitory signaling by NK receptors and
FcgRIIb (69).
Modulation of CTLA-4 activity promises to be a power-
ful option for manipulation of immune responses. The pos-
sibilities for this modulation are currently confined to the
use of anti–CTLA-4 antibodies. Therefore, a more detailed
understanding is required of the mechanisms used by this
receptor for its downregulation of IL-2 production. Possi-
bly a molecular understanding of CTLA-4 action may offer
novel opportunities for downregulating undesired responses
or stimulating useful ones. In the present study, we have
shown that the molecular target(s) for CTLA-4–mediated
interference with IL-2 production lie(s) upstream of ERK
and JNK, but downstream of TCR-z. Identification of this
target will be a major focus for the future.
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